Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 51,216 shares of the biotechnology company’s stock, valued at approximately $358,000. Simplify Asset Management Inc. owned 0.55% of Benitec Biopharma as of its most recent SEC filing.
Separately, GAMMA Investing LLC grew its holdings in Benitec Biopharma by 53.0% during the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 1,884 shares in the last quarter. 52.19% of the stock is owned by hedge funds and other institutional investors.
Benitec Biopharma Stock Performance
Shares of BNTC opened at $8.63 on Friday. The firm has a fifty day simple moving average of $8.96 and a 200 day simple moving average of $7.71. Benitec Biopharma Inc. has a 12 month low of $2.69 and a 12 month high of $10.88. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $80.80 million, a price-to-earnings ratio of -4.70 and a beta of 0.90.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Benitec Biopharma
About Benitec Biopharma
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Articles
- Five stocks we like better than Benitec Biopharma
- Golden Cross Stocks: Pattern, Examples and Charts
- Cracker Barrel Is at the Bottom of the Barrel: Time to Buy?
- Most Volatile Stocks, What Investors Need to Know
- Why Shopify Stock Has Analysts Buzzing About Big Gains
- Using the MarketBeat Stock Split Calculator
- Roku Stock Gains New Buy Rating: Here’s Why Analysts Are Bullish
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.